A new standard of care for patients with surgically unresectable stage III non-small cell lung cancer

被引：1

作者：

Gill, Harpaul S. ^{[1
]}

Ramalingam, Suresh S. ^{[1
]}

机构：

[1] Emory Univ, Sch Med, Dept Hematol & Oncol, Winship Canc Inst, 1365 Clifton Rd NE,Bldg C,Suite 4014, Atlanta, GA 30322 USA

来源：

CANCER | 2019年 / 125卷 / 13期

关键词：

durvalumab; immune checkpoint inhibition; NSCLC; PACIFIC trial; stage III NSCLC; RANDOMIZED PHASE-III; RADIATION-THERAPY; CONCURRENT CHEMORADIOTHERAPY; SEQUENTIAL CHEMORADIOTHERAPY; CONSOLIDATION DOCETAXEL; THORACIC RADIOTHERAPY; TRIAL; CHEMOTHERAPY; COMBINATION; CARBOPLATIN;

D O I：

10.1002/cncr.31996

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Overall survival data from the PACIFIC trial have reaffirmed earlier US Food and Drug Administration approval of durvalumab in patients with stage III non-small cell lung cancer. In the current commentary, the authors provide a brief historical perspective on stage III disease as well as a further analysis of the strengths and weaknesses of the trial.

引用

页码：2148 / 2153

页数：6

共 50 条

[41] Induction treatment in patients with stage III non-small cell lung cancer
Palmero, Ramon
Vilarino, Noelia
Navarro-Martin, Arturo
Nadal, Ernest
TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (01) : 539 - 554
[42] TIME TO TREATMENT IN PATIENTS WITH STAGE III NON-SMALL CELL LUNG CANCER
Wang, Li
Correa, Candace R.
Hayman, James A.
Zhao, Lujun
Cease, Kemp
Brenner, Dean
Arenberg, Doug
Curtis, Jeffery
Kalemkerian, Gregory P.
Kong, Feng-Ming
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 74 (03): : 790 - 795
[43] Radiation and chemotherapy for patients with stage III non-small cell lung cancer
Green, MR
Lima, CMR
Sherman, CA
SEMINARS IN RADIATION ONCOLOGY, 2000, 10 (04) : 289 - 295
[44] Adjuvant chemotherapy in non-small cell lung cancer: A new standard of care?
Pirker, R.
LUNG CANCER, 2006, 52 : S13 - S13
[45] Comparison of chemotherapy regimens for concurrent chemoradiotherapy in unresectable stage III non-small cell lung cancer
Harada, Hideyuki
Yamamoto, Nobuyuki
Takahashi, Toshiaki
Endo, Masahiro
Murakami, Haruyasu
Tsuya, Asuka
Nakamura, Yukiko
Ono, Akira
Igawa, Satoshi
Shukuya, Takehito
Tamiya, Akihiro
Nishimura, Tetsuo
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2009, 14 (06) : 507 - 512
[46] The evolving landscape of stage III unresectable non-small cell lung cancer "between lights and shadows"
Delcuratolo, Marco Donatello
Crespi, Veronica
Saba, Giorgio
Mogavero, Andrea
Napoli, Valerio Maria
Garbo, Edoardo
Cani, Massimiliano
Ungaro, Antonio
Reale, Maria Lucia
Merlini, Alessandra
Capelletto, Enrica
Bironzo, Paolo
Levis, Mario
Ricardi, Umberto
Novello, Silvia
Passiglia, Francesco
CANCER TREATMENT REVIEWS, 2025, 135
[47] The safety and efficacy of induction chemoimmunotherapy in initially unresectable stage III non-small cell lung cancer
Tang, Min
Zhao, Zhe
Zhang, Ping
Nie, Xin
Wu, Xiaonan
Yuan, Yue
Liu, Lian
Liu, Lipin
Jiao, Peng
Li, Lin
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[48] Smooth sailing for immunotherapy for unresectable stage III non-small cell lung cancer: the PACIFIC study
Khandekar, Melin J.
Jain, Rakesh
TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S16 - S20
[49] Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer
Melosky, Barbara
Juergens, Rosalyn
McLeod, Deanna
Leighl, Natasha
Brade, Anthony
Card, Paul B.
Chu, Quincy
LUNG CANCER, 2019, 134 : 259 - 267
[50] Induction chemotherapy followed by concurrent chemoradiotherapy in stage III unresectable non-small cell lung cancer
Tan, EH
Wee, J
Ang, PT
Fong, KW
Leong, SS
Khoo, KS
Tan, T
Lee, KS
Eng, P
Hsu, A
Tan, YK
Chua, EJ
Ong, YY
ACTA ONCOLOGICA, 1999, 38 (08) : 1005 - 1009

← 1 2 3 4 5 →